pharmaphorum5 天
NICE relents and okays Akcea’s rare disease drug Waylivra for NHS use
Patients with the rare disease familial chylomicronemia syndrome (FCS) will be able to access treatment with Akcea’s Waylivra via the ... founder and chair of the Action FCS medical charity ...
pharmaphorum5 年
Akcea's rare disease drug Waylivra way too pricey for NHS, says NICE
But NICE estimated Waylivra’s cost per QALY was £481,508 – and even Akcea’s own estimates were substantially higher than the threshold at £260,587 per QALY gained.